Pesquisar
Jazz Pharmaceuticals PLC
JAZZAdicionar à lista de desejos
230.479USD
+0.629+0.27%
Horário de mercado （ET）Cotações atrasadas em 15 min
14.16BValor de mercado
558.95P/L TTM
Mais detalhes de Jazz Pharmaceuticals PLC Empresa
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Informações de Jazz Pharmaceuticals PLC
Código da empresaJAZZ
Nome da EmpresaJazz Pharmaceuticals PLC
Data de listagemJan 18, 2012
CEOGala (Renee D)
Número de funcionários2800
Tipo de títulosOrdinary Share
Fim do ano fiscalJan 18
EndereçoFifth Floor, Waterloo Exchange
CidadeDUBLIN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIreland
Código postal- -
Telefone35316347800
Sitehttps://www.jazzpharma.com/
Código da empresaJAZZ
Data de listagemJan 18, 2012
CEOGala (Renee D)
Executivos da empresa Jazz Pharmaceuticals PLC
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Seamus C. Mulligan
Mr. Seamus C. Mulligan
Independent Director
Independent Director
1.28M
+0.54%
Mr. Bruce C. Cozadd
Mr. Bruce C. Cozadd
Chairman of the Board
Chairman of the Board
333.80K
-1.80%
Ms. Renee D. Gala
Ms. Renee D. Gala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
57.88K
-1.04%
Dr. Robert Iannone, M.D.
Dr. Robert Iannone, M.D.
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
49.19K
+18.01%
Mr. Philip L. Johnson
Mr. Philip L. Johnson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
28.23K
+27.29%
Ms. Neena M. Patil, J.D.
Ms. Neena M. Patil, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
23.43K
-5.12%
Ms. Samantha Pearce
Ms. Samantha Pearce
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
22.79K
+25.35%
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Director
Independent Director
17.65K
+30.00%
Ms. Anne O'Riordan
Ms. Anne O'Riordan
Independent Director
Independent Director
16.50K
+21.25%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
10.84K
+32.36%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Seamus C. Mulligan
Mr. Seamus C. Mulligan
Independent Director
Independent Director
1.28M
+0.54%
Mr. Bruce C. Cozadd
Mr. Bruce C. Cozadd
Chairman of the Board
Chairman of the Board
333.80K
-1.80%
Ms. Renee D. Gala
Ms. Renee D. Gala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
57.88K
-1.04%
Dr. Robert Iannone, M.D.
Dr. Robert Iannone, M.D.
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
49.19K
+18.01%
Mr. Philip L. Johnson
Mr. Philip L. Johnson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
28.23K
+27.29%
Ms. Neena M. Patil, J.D.
Ms. Neena M. Patil, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
23.43K
-5.12%
Perguntas frequentes
Quem são os cinco principais acionistas de Jazz Pharmaceuticals PLC?
Os cinco principais acionistas de Jazz Pharmaceuticals PLC são: Mr. Seamus C. Mulligan
Quantas instituições possuem ações da Jazz Pharmaceuticals PLC (JAZZ)?
Em 2026Q1, 1229 instituições possuíam ações da Jazz Pharmaceuticals PLC, com valor de mercado aproximado de 70.31M, representando 112.06% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -754072.00.
Qual é a maior fonte de receita da Jazz Pharmaceuticals PLC?
Em 2026Q1, o segmento de negócios Xywav gerou a maior receita para Jazz Pharmaceuticals PLC, totalizando 1.66B e representando 38.83% da receita total.
